Interferon-γ is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/Interleukin-2 and mediates its antitumor activity n vivo

Journal of Interferon and Cytokine Research

Volumn 29, Issue 8, 2009, Pages 451-459

  Fan, Keke ^a   Borden, Ernest ^a   Yi, Taolin ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 5; STIBOGLUCONATE SODIUM;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TUMOR GROWTH; WILD TYPE;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIMONY SODIUM GLUCONATE; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH INHIBITORS; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-5; KIDNEY NEOPLASMS; LECTINS, C-TYPE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; SIGNAL TRANSDUCTION;

EID: 68949091744     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0061     Document Type: Article

References (39)

1. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA, Neel BG. 2004. Mouse model of Noonan syndrome reveals cell type- and gene dosage- dependent effects of Ptpn11 mutation. Nat Med 10:849-857.
2. Becker Y. 2006. Molecular immunological approaches to biotherapy of human cancers - a review, hypothesis and implications. Anticancer Res 26:1113-1134.
3. Berman JD. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 10:560-586.
4. Berman JD. 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684-703.
5. Borden EC. 2000. Reducing primary melanoma mortality. Curr Oncol Rep 2:289-291.
6. Borden EC. 2005. Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res 25:511-527
7. Chang AE, Rosenberg SA. 1989. Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol 5:385-390.
8. Cheung MC, Pantanowitz L, Dezube BJ. 2005. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 10:412-426.
9. David M, Chen HE, Goelz S, Larner AC, Neel BG. 1995. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol 15:7050-7058.
10. D0eng C, Minguela A, Hussain RZ, Lovett-Racke AE, Radu C, Ward ES, Racke MK. 2002. Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis. J Immunol 168:4511-4518.
11. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. 2001a. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042.
12. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. 2001b. Efficacy and safety of a specific inhibitor of the BCR- ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037.
13. Easty D, Gallagher W, Bennett DC. 2006. Protein tyrosine phos- phatases, new targets for cancer therapy. Curr Cancer Drug Targets 6:519-532.
14. Fan K, Zhou M, Pathak MK, Lindner DJ, Altuntas CZ, Tuohy VK, Borden EC, Yi T. 2005. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages. J Immunol 175:7003-7008.
15. Jiao H, Yang W, Berrada K, Tibrizi M, Shultz L, Yi T. 1997. Macrophages from motheaten and viable motheaten mutant mice show increased proliferative response to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction. Exp Hematol 25:592-600.
16. Kamata T, Yamashita M, Kimura M, Murata K, Inami M, Shimizu C, Sugaya K, Wang CR, Taniguchi M, Nakayama T. 2003. src ho- mology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J Clin Invest 111:109-119.
17. Kim R, Emi M, Tanabe K. 2006. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119:254-264.
18. Kirchner GI, Franzke A, Buer J, Beil W, Probst-Kepper M, Wittke F, Overmann K, Lassmann S, Hoffmann R, Kirchner H, Ganser A, Atzpodien J. 1998. Pharmacokinetics of recombinant human in- terleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol 46:5-10.
19. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. 1995. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80:729-738.
20. Li J, Lindner DJ, Farver C, Borden EC, Yi T. 2006. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG antitumor action. Cancer Chemother Pharmacol. 60:341-349.
21. Lindner DJ, Borden EC, Kalvakolanu DV. 1997. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 3:931-937.
22. McDermott DF, Atkins MB. 2006. Interleukin-2 therapy of meta- static renal cell carcinoma-predictors of response. Semin Oncol 33:583-587.
23. Migone TS, Cacalano NA, Taylor N, Yi T, Waldmann TA, Johnston JA. 1998. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc Natl Acad Sci USA 95:3845-3850.
24. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G,Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. 2006. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524. (Pubitemid 43854967)
25. Pathak MK, Yi T. 2001. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 167:3391-3397.
26. Rees PH, Keating MI, Kager PA, Hockmeyer WT. 1980. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 2:226-229.
27. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferon- gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163-189.
28. Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, Matthews RJ, Thomas ML, Beier DR. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phos-phatase (Hcph) gene. Cell 73:1445-1454.
29. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. 2005. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972. (Pubitemid 46202316)
30. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465-468.
31. Tonks NK. 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7:833-846.
32. Tsui FW, Martin A, Wang J, Tsui HW. 2006. Investigations into the regulation and function of the SH2 domain-containing proteintyrosine phosphatase, SHP-1. Immunol Res 35:127-136.
33. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 4:124-129.
34. Yi T, Ihle JN. 1993. Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand. Mol Cell Biol 13:3350-3358.
35. Yi T, Mui AL, Krystal G, Ihle JN. 1993. Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor beta chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol Cell Biol 13:7577-7586.
36. Yi T, Pathak MK, Lindner DJ, Ketterer ME, Farver C, Borden EC. 2002. Anticancer activity of sodium stibogluconate in synergy with IFNs. J Immunol 169:5978-5985.
37. Yi T, Zhang J, Miura O, Ihle JN. 1995. Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epoinduced receptor tyrosine phosphorylation:identification of potential binding sites. Blood 85:87-95.
38. Yu WM, Wang S, Keegan AD, Williams MS, Qu CK. 2005. Abnormal Th1 cell differentiation and IFN-gamma production in T lymphocytes from motheaten viable mice mutant for Src homology 2 domain-containing protein tyrosine phosphatase-1. J Immunol 174:1013-1019.
39. Zhang J, Somani AK, Siminovitch KA. 1999. Roles of the SHP-1 tyro- sine phosphatase in the negative regulation of cell signalling. Semin Immunol 12:361-378.